Home / Treatments / Osteochondral Allograft
Osteochondral Allograft denials: what the review data shows
Independent reviewers have decided 12 published cases where an insurer denied Osteochondral Allograft — and they overturned the insurer 66.7% of the time. A denial for Osteochondral Allograft is a starting position, not a final answer.
Published decisions
12
2001–2026
Overturned
66.7%
8 denials reversed
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 9 | 66.7% |
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 3 | 66.7% |
Typical time to a decision
21 days
Most land between 13 and 21 days
Handled as urgent
16.7%
Expedited when a delay would cause harm
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: This patient has a history of chronic right knee pain. Conservative treatment has included exercise, activity modification, corticosteroid injection, stem cell injection, physical therapy, ice, bracing, and acupuncture. An x-ray series documented moderate medial patellofemoral osteoarthritis. There was mild bilateral genu varus with approximately equal leg lengths. The patient reported he was unable to tolerate running. Right knee physical examination documented no effusion, negative Steinmann and McMurray’s, negative Hoffa fat pad test, neutral patellar tilt, and no pain or tenderness to palpation over the medial or lateral joint lines, trochlea, tibial tubercle, patellar tendon, or pes anserine. He had some pain in the anteromedial aspect of his knee with step-down test and full weight bearing.
Physician 1: The patient is a 44-year-old woman with long-standing knee pain and is status post multiple surgical procedures. Her most recent surgery was an osteochondral allograft procedure in 2003. Although the patient initially experienced relief following the procedure, her pain has now returned. The patient’s provider has requested authorization for a revisional osteochondral allograft procedure, which has been denied by the Health Plan as investigational in nature.Osteochondral allografting for the treatment of chondral lesions is neither experimental nor investigational. It is a procedure that is utilized in cases such as this to provide cartilaginous covering in patients of relatively young age who have lost cartilage. There are no viable treatment options for the patient other than replacement-type surgery, which is undesirable in younger patients.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Physician 1: The patient is a 26-year-old female who is post anterior cruciate ligament (ACL) repair. She is experiencing pain and loss of motion and is unable to obtain relief with standard treatment modalities. Her provider has recommended she undergo an osteochondral allograft procedure. The Health Plan has denied this request on the basis that the requested procedure is considered investigational.There is no literature regarding the use of osteochondral allograft for focal defects of the knee after ACL reconstruction surgery. This patient now has established arthritis. Allografting the cartilage defects is not likely to be successful in this clinical setting. Given the lack of scientific data, the efficacy of the requested procedure remains unproven at this time and therefore, it cannot be recommended.
Nature of Statutory Criteria/ Case Summary: The enrollee is requesting authorization and coverage for an open osteochondral allograft of the left knee. The enrollee suffered a knee injury while playing basketball. He was unable to ambulate. The enrollee underwent arthroscopic medial meniscus repair and partial lateral meniscectomy, and medial and lateral femoral condyle chondroplasty. A post-surgical re-evaluation reported the enrollee will need a second surgery to the medial femoral condyle and a chondral allograft.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
How to use this in your appeal
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for Osteochondral Allograftwhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.